Efficacy and Safety of Xiaoyao Recipe in the Treatment of Poststroke Depression: A Systematic Review and Meta-Analysis. (13th April 2022)

• Record Type: Journal Article
• Authors: Wang, Dou; Li, Tao; Ron, Jie; Mao, Meiling; Yang, Yifan; Feng, Yalun; Yan, Yongmei
• Other Names: Oliveira Mozaniel Academic Editor.
• Is Part Of: Evidence-based complementary and alternative medicine. Volume 2022(2022)
• Publication Date: 2022-04-13
• Subjects: Alternative medicine -- Periodicals; 615.505
• DOI: 10.1155/2022/4385783
• Languages: English
• ISSNs: 1741-427X

Abstract

Abstract : Background . Poststroke depression (PSD) is a common neuropsychiatric disorder that affects the disability, mortality, functional recovery, and quality of daily life of patients. Xiaoyao Recipe (XYR) is often used to treat PSD and has achieved good clinical effects, but it lacks reliable evidence. Objective . This study aims to evaluate the effectiveness and safety of XYR on PSD through meta-analysis. Methods . A comprehensive literature search was carried out in multiple databases, including PubMed, the Cochrane Library, Chinese Biomedical Literature Service System, China National Knowledge Infrastructure, Wanfang Database, VIP Database, and ClinicalTrials, from inception to July 1, 2021, to collect randomized controlled trials that applied XYR for patients with PSD. For a controlled trial, the search time limit was set from the time of the database's establishment to July 2021. Two experienced researchers independently screened the literature according to the inclusion and exclusion criteria, extracted data, evaluated the quality of the literature, and used RevMan 5.3 software for meta-analysis. Results . A total of 12 studies were included in this study, involving 882 patients with PSD who were hospitalized or outpatients. The meta-analysis results showed that the total effective rate (p < 0.00001 ) of the test group (XYR or XYR combined with antidepressants) after treatment was high; Hamilton's Depression Scale score (p < 0.000001 ), Scandinavian Stroke Scale score (p = 0.004 < 0.05 ), and Barthel index (p < 0.00001 ) were improved; the incidence of adverse reactions (p < 0.00001 ) was low; and the serum serotonin content (p < 0.00001 ) was high. Conclusion . Compared with antidepressant drugs, XYR is more effective and safer in the treatment of PSD patients. However, more high-quality studies are needed to further support the above conclusions.